Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Recent studies have attempted to address this question. Various claims have been made about the dual-acting antidepressants, including: (1) they result in a higher remission rate; (2) they have a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results